Short answer
Design Therapeutics, Inc. (DSGN) filed an 8-K current report with the SEC on May 18, 2026 reporting Item 8.01 (Other Events). Phase 1/2 RESTORE-FA data support DT-216P2 activity in Friedreich ataxia after four weeks across 16 treated patients.
Design Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Phase 1/2 RESTORE-FA data support DT-216P2 activity in Friedreich ataxia after four weeks across 16 treated patients
- At 1 mpk, mean improvements reached 6.4 points on mFARS and 2.7 points on Upright Stability Score
- FXN biomarkers increased in blood and muscle, including 65% blood mRNA and 42% muscle mRNA from baseline
- Generally well-tolerated, with no serious adverse events or discontinuations; three patients had transient ALT elevations
- Company plans a registrational development path, with an update expected in Q4 2026
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Design Therapeutics, Inc. 8-K filings
Get the next DSGN 8-K as it lands
Follow DSGN for push alerts, or ask the research agent what this filing means.